While the Buy rating indicates continued confidence in Entrada Therapeutics' potential, the reduction in price target may reflect a reassessment of near-term growth expectations or perceived risks. This could lead to mixed reactions in the short term, as investors weigh the positive endorsement against the lowered price expectations.